ParaPro Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: Carmel IN United States (2002)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2005
NCT00858481
First Marketed Drug
2011
spinosad (natroba)
First NDA Approval
2011
spinosad (natroba)
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

ParaPRO LLC | PARAPRO LLC

Active Ingredients

Marketed Drugs (1)

spinosad (natroba) (2011 NDA)

Drugs in Phase 4 Trials (1)

spinosad (natroba) (12 trials)

Drugs in Phase 3 Trials (1)

permethrin (nix) (3 trials)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Approved Indications


 

Lice Infestations

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis, Photoallergic (Phase 1)

Lice Infestations (Phase 4)

Parasitic Diseases (Phase 3)

Scabies (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 3